The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors. FDA approves an all-oral treatment for newly ...

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...

Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...

Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Andrew Kuykendall, MD, discusses where rusfertide (Mimrylo) may fit within the treatment paradigm for polycythemia vera and ...

Out-of-pocket costs drove abandonment: fill rates fell from ~80% at ≤$15 to ~30% at $500–$2000, and to 21.6% when >$2000 commercially. Prior authorization dominated rejection reasons (32.1% Medicare; ...

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty. In this episode of The ...

A medical oncologist discusses the significance of recent data and CAR T-cell therapy approvals in early relapsed/refractory multiple myeloma. An expert on multiple myeloma provides a comprehensive ...

Ubamatamab redirects T cells via CD3 engagement to MUC16-expressing tumor cells, leveraging uniformly high MUC16 expression in LGSOC and enabling responses without molecular preselection. At 800 mg ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...